<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>201-EFAVIRENZ.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AG03" />
<ATC code="J05AR06" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>201-EFAVIRENZ.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AG03" />
<ATC code="J05AR06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ATAZANAVIR" rxcui="343047">
<ATC code="J05AE08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the atazanavir due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>201-EFAVIRENZ.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AG03" />
<ATC code="J05AR06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ATOVAQUONE" rxcui="60212">
<ATC code="P01AX06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of atovaquone by the enzymatic inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>201-EFAVIRENZ.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AG03" />
<ATC code="J05AR06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIHYDROERGOTAMINE" rxcui="3418">
<ATC code="N02CA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>201-EFAVIRENZ.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AG03" />
<ATC code="J05AR06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERGOTAMINE" rxcui="4025">
<ATC code="N02CA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye.)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION </SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>201-EFAVIRENZ.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AG03" />
<ATC code="J05AR06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="FOSAMPRENAVIR" rxcui="358262">
<ATC code="J05AE07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the amprenavir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>201-EFAVIRENZ.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AG03" />
<ATC code="J05AR06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="INDINAVIR" rxcui="114289">
<ATC code="J05AE02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the indinavir</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>201-EFAVIRENZ.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AG03" />
<ATC code="J05AR06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PIMOZIDE" rxcui="8331">
<ATC code="N05AG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>201-EFAVIRENZ.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AG03" />
<ATC code="J05AR06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFABUTIN" rxcui="55672">
<ATC code="J04AB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease by about half of the concentrations of rifabutin, due to increase of its hepatic metabolism by the efavirenz</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>201-EFAVIRENZ.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AG03" />
<ATC code="J05AR06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the efavirenz due to increase of its hepatic metabolism by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>201-EFAVIRENZ.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AG03" />
<ATC code="J05AR06" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the efavirenz</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
</INTERACTIONS>
